Two new sub-types of multiple sclerosis (MS) were discovered by researchers from Queen Square Analytics and University ...
A single dose of Immutep’s MS therapy, IMP761, was well tolerated and reduced T-cell activity for up to 23 days in healthy ...
Annual out-of-pocket treatment costs for multiple sclerosis increased by 125% from 2002 to 2021 in the US, driven mainly by ...
At Multiple Sclerosis News Today, stories about the keto diet, myelin repair, and vitamin D topped this year's most-read list ...
An experimental drug shows promise as an effective new approach for treating multiple sclerosis and the intestinal ailment Crohn's disease. In preliminary tests, the new drug Antegren dramatically ...
A drug originally developed to treat leukemia has shown promising results for multiple sclerosis patients in the United Kingdom. MS is an auto-immune disease that affects millions of people, including ...
Using artificial intelligence (AI), researchers looked at brain scans and tested for a blood marker for nerve cell injury and ...
B-cell depletion is effective in MS and NMOSD, with anti-CD20 and anti-CD19 mAbs showing distinct mechanisms impacting safety and tolerability. Glycoengineering enhances ADCC activity, mitigating ...
A phase 3, randomized, parallel-group trial showcased the efficacy of internet-based cognitive behavioral therapy (iCBT) for combatting depressive symptoms brought on by multiple sclerosis (MS). An ...
Many symptoms of MS are the same as those of other conditions. If you are concerned that you may have MS, make an appointment with your primary care provider. They will discuss your concerns and do a ...
Doctors have traditionally used a "step-up," also known as the "escalation," approach for treating multiple sclerosis (MS), the neurodegenerative disease that affects the central nervous system. Using ...
Therapeutic monoclonal antibodies (mAbs) are potent new tools for a molecular targeted approach to modify the course of multiple sclerosis (MS). Besides natalizumab, which was approved in 2006, three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback